WEBULL
WebtradeDownload

Sarepta Therapeutics (SRPT) ELEVIDYS Data Puts Its Valuation Story Back In Focus

Simply Wall St · 2d ago

New ELEVIDYS data reshapes the Sarepta Therapeutics story

Sarepta Therapeutics (SRPT) just presented new ELEVIDYS gene therapy data to specialists at the World Muscle Society congress, extending the evidence to older Duchenne patients and reinforcing protein expression findings in very young children.

ELEVIDYS is arriving at a tricky moment for Sarepta Therapeutics investors. The share price has fallen 22.22% over the last 30 days and is down 17.88% year to date, while the 1 year total shareholder return is lower by 25.15%. This signals that confidence has been fading even as fresh clinical data start to reframe the risk and opportunity around the Duchenne franchise.

Pursue the Duchenne gene therapy theme beyond Sarepta Therapeutics by scanning a curated group of rare disease and biotech players with 20 high quality undiscovered gems for potential under-the-radar opportunities.

Sarepta Therapeutics now trades at a steeply marked down US$17.50 while the consensus fair value sits higher. How wide is the gap investors are really underwriting here?

Most Popular Narrative: 19.5% Undervalued

Sarepta Therapeutics last closed at $17.50, while the most followed valuation narrative pegs fair value closer to $21.73. The market is treating today's price as a sizeable discount that depends on how the Duchenne cash engine supports the pipeline.

Sarepta Therapeutics is using a cash flow positive Duchenne muscular dystrophy portfolio, with Q2 2026 product gross margins of 75% and non GAAP operating income of US$86 million, to self fund pipeline work and potentially support future earnings and cash generation without relying on new equity.

See why 41 investors see Sarepta Therapeutics as 19% undervalued.

Result: Fair Value of $21.73 (UNDERVALUED)

Still, the Sarepta Therapeutics narrative can break if ELEVIDYS safety concerns resurface or if competitive exon skipping therapies chip away at the Duchenne cash engine.

Find out about the key risks to this Sarepta Therapeutics narrative.

Next Steps

Mixed about the tone of this Sarepta Therapeutics story so far. The fastest way to cut through both the concern around risks and the optimism around rewards is to review the data for yourself, then pressure test that view against the 2 key rewards and 1 important warning sign.

Looking for more Sarepta Therapeutics style ideas?

If Sarepta Therapeutics has your attention, do not stop there. Broaden your watchlist with data backed filters that surface targeted opportunities other investors may overlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.